Printed From BioPortfolio.com
Adalimumab biosimilar ABP 501 shows similar efficacy, safety and immunogenicity
04:37 EDT 13 Oct 2017 | Generics and Biosimilars Initiative
Biosimilars are defined by the US Food and Drug Administration (FDA) as a biological product that is ‘highly similar to’ an approved biological product (the ‘reference’ or ‘originator’ or ‘bio-originator’ product) and that has ‘no clinically meaningful differences’ in safety or effectiveness compared to the reference product.
Original Article: Adalimumab biosimilar ABP 501 shows similar efficacy, safety and immunogenicity
